Although sustained Ca2+ responses were noted as adverse events in normal pancreatic acinar cells treated with early-generation BCL-2 inhibitors, the safety of venetoclax was confirmed in pancreatic cancer treatment, as it could maintain intracellular calcium homeostasis in normal cells [154]. The gene discussed is BCL2; the disease is pancreatic neoplasm.